Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 1
1981 1
1985 2
1987 2
1990 4
1992 4
1993 3
1994 1
1996 1
1997 1
1999 1
2000 3
2002 3
2003 5
2004 3
2005 18
2006 14
2007 17
2008 21
2009 31
2010 33
2011 37
2012 58
2013 78
2014 82
2015 97
2016 80
2017 119
2018 92
2019 124
2020 132
2021 171
2022 195
2023 192
2024 83

Text availability

Article attribute

Article type

Publication date

Search Results

1,476 results

Results by year

Filters applied: . Clear all
Page 1
Azacitidine maintenance in AML post induction and posttransplant.
Bewersdorf JP, Prebet T, Gowda L. Bewersdorf JP, et al. Curr Opin Hematol. 2022 Mar 1;29(2):84-91. doi: 10.1097/MOH.0000000000000700. Curr Opin Hematol. 2022. PMID: 35013047 Review.
Prolonging the duration of remission with minimal nonrelapse mortality risk is an area of unmet need for AML patients. RECENT FINDINGS: In QUAZAR AML-001 study, the oral azacitidine analogue CC-486 demonstrated an overall survival (OS) benefit when given as p …
Prolonging the duration of remission with minimal nonrelapse mortality risk is an area of unmet need for AML patients. RECENT FINDING …
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. DiNardo CD, et al. Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25. Blood. 2019. PMID: 30361262 Free PMC article.
Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance. ...Patients (N = 145) were at least 65 years old with treatment-n …
Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpressi …
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, Lin D, Chen Y, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Yin Z, Xuan L, Lin R, Jiang X, Yu G, Liu Q. Jin H, et al. J Hematol Oncol. 2023 Apr 29;16(1):42. doi: 10.1186/s13045-023-01437-1. J Hematol Oncol. 2023. PMID: 37120593 Free PMC article. Clinical Trial.
BACKGROUND: Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax combined with azacitidine plus homoharringtonine (VAH) regimen for R/R AML. ...RES …
BACKGROUND: Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal prognosis. The aim of this study was to investigate …
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne B, Zhong J, Beach CL, Risueño A, Menezes DL, Ossenkoppele G, Döhner H. Roboz GJ, et al. Blood. 2022 Apr 7;139(14):2145-2155. doi: 10.1182/blood.2021013404. Blood. 2022. PMID: 34995344 Free article. Clinical Trial.
Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse and poor survival. Postremission maintenance therapy that prolongs MRD negativity or converts MRD+ patients to MRD- stat …
Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predicti …
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients.
Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. Oran B, et al. Blood Adv. 2020 Nov 10;4(21):5580-5588. doi: 10.1182/bloodadvances.2020002544. Blood Adv. 2020. PMID: 33170934 Free PMC article. Clinical Trial.
This study investigated the efficacy and safety of azacitidine maintenance in the posttransplant setting based on the encouraging phase 1/2 reports for azacitidine maintenance in patients with acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). ...Medi …
This study investigated the efficacy and safety of azacitidine maintenance in the posttransplant setting based on the encouraging pha …
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Pollyea DA, et al. Bone Marrow Transplant. 2022 Feb;57(2):160-166. doi: 10.1038/s41409-021-01476-7. Epub 2021 Oct 13. Bone Marrow Transplant. 2022. PMID: 34645926
The combination of venetoclax (ven) and azacitidine (aza) has resulted in high response rates in the upfront treatment of AML in patients age > 75 and patients unfit for intensive chemotherapy. ...Our data suggest that ven/aza followed by SCT in newly diagnosed …
The combination of venetoclax (ven) and azacitidine (aza) has resulted in high response rates in the upfront treatment of AML …
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
Wei AH, Döhner H, Sayar H, Ravandi F, Montesinos P, Dombret H, Selleslag D, Porkka K, Jang JH, Skikne B, Beach CL, Prebet T, Zhang G, Risueño A, Ugidos M, See WL, Menezes D, Roboz GJ. Wei AH, et al. Am J Hematol. 2023 Apr;98(4):E84-E87. doi: 10.1002/ajh.26847. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36655608 Free article. Clinical Trial. No abstract available.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
BACKGROUND: Although induction chemotherapy results in remission in many older patients with acute myeloid leukemia (AML), relapse is common and overall survival is poor. METHODS: We conducted a phase 3, randomized, double-blind, placebo-controlled trial of the oral formul …
BACKGROUND: Although induction chemotherapy results in remission in many older patients with acute myeloid leukemia (AML), relapse is …
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax.
Waclawiczek A, Leppä AM, Renders S, Stumpf K, Reyneri C, Betz B, Janssen M, Shahswar R, Donato E, Karpova D, Thiel V, Unglaub JM, Grabowski S, Gryzik S, Vierbaum L, Schlenk RF, Röllig C, Hundemer M, Pabst C, Heuser M, Raffel S, Müller-Tidow C, Sauer T, Trumpp A. Waclawiczek A, et al. Cancer Discov. 2023 Jun 2;13(6):1408-1427. doi: 10.1158/2159-8290.CD-22-0939. Cancer Discov. 2023. PMID: 36892565 Free PMC article.
The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently transforming acute myeloid leukemia (AML) therapy. ...SIGNIFICANCE: Venetoclax/azacitidine treatment has become an alternative to standard chemotherapy for patients with …
The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently transforming acute myeloid leukemia (AML …
Ivosidenib and Azacitidine in IDH1-Mutated AML.
Goodman AM, Mohyuddin GR, Prasad V. Goodman AM, et al. N Engl J Med. 2022 Jun 30;386(26):2536. doi: 10.1056/NEJMc2206489. N Engl J Med. 2022. PMID: 35767449 No abstract available.
1,476 results

Searches related to "aml azacitidine"